Table 1.
Characteristics of the study population (primary efficacy cohort)
| Ad5-nCoV (n=10660*) | Placebo (n=10590†) | ||
|---|---|---|---|
| Mean age at consent (range, SD), years | 37·8 (18·0–89·3, 13·8) | 37·7 (18·0–93·5, 13·7) | |
| Age distribution | |||
| 18–44 years | 7623 (71·5%) | 7579 (71·6%) | |
| 45–59 years | 2198 (20·6%) | 2171 (20·5%) | |
| ≥ 60 years | 839 (7·9%) | 840 (7·9%) | |
| Sex‡ | |||
| Male | 7452 (69·9%) | 7578 (71·6%) | |
| Female | 3208 (30·1%) | 3012 (28·4%) | |
| Gender‡ | |||
| Male | 7468 (70·1%) | 7590 (71·7%) | |
| Female | 3192 (29·9%) | 2998 (28·3%) | |
| Transgender woman | 0 | 1 (<0·1%) | |
| Transgender man | 0 | 1 (<0·1%) | |
| Ethnicity‡ | |||
| Hispanic or Latino | 4006 (37·6%) | 3953 (37·3%) | |
| Other | 6654 (62·4%) | 6637 (62·7%) | |
| Race‡ | |||
| Data missing | 18 (0·2%) | 21 (0·2%) | |
| Indigenous, Americas§ | 876 (8·2%) | 875 (8·3%) | |
| Asian | 6230 (58·4%) | 6216 (58·7%) | |
| Black | 3 (<0·1%) | 4 (<0·1%) | |
| White | 1037 (9·7%) | 1019 (9·6%) | |
| Mixed race | 2496 (23·4%) | 2455 (23·2%) | |
| Mean BMI (range, SD) | 25·5 (11·2–77·1, 5.2) | 25·6 (13·5–74·6, 5.3) | |
| BMI category | |||
| ≥30·0 | 1863 (17·5%) | 1850 (17·5%) | |
| 25·0–29·9 | 3569 (33·5%) | 3588 (33·9%) | |
| 18·5–24·9 | 4529 (42·5%) | 4389 (41·4%) | |
| 0 to <18·4 | 699 (6·6%) | 763 (7·2%) | |
Data are n (%) unless otherwise stated. Ad5-nCoV=adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein.
*
Two participants who were randomly assigned to receive Ad5-nCoV and instead received placebo.
†
Two participants who were randomly assigned to receive placebo and instead received Ad5-nCoV.
‡
Sex, gender, ethnicity, and race were determined by self-report.
§
This category includes individuals indigenous to the Americas (eg, Mayan, Diaguita, Mapuche, and Huilliche).